Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $722000.0.

  • Cartesian Therapeutics' Receivables - Net fell 8504.87% to $722000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $722000.0, marking a year-over-year decrease of 8504.87%. This contributed to the annual value of $872000.0 for FY2024, which is 8514.48% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Receivables - Net of $722000.0 as of Q3 2025, which was down 8504.87% from $354000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Receivables - Net high stood at $32.0 million for Q2 2024, and its period low was $354000.0 during Q2 2025.
  • Moreover, its 5-year median value for Receivables - Net was $6.6 million (2022), whereas its average is $7.6 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Receivables - Net surged by 49496.75% in 2024 and then tumbled by 9889.51% in 2025.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Receivables - Net stood at $9.9 million in 2021, then crashed by 33.47% to $6.6 million in 2022, then decreased by 11.01% to $5.9 million in 2023, then plummeted by 85.14% to $872000.0 in 2024, then decreased by 17.2% to $722000.0 in 2025.
  • Its last three reported values are $722000.0 in Q3 2025, $354000.0 for Q2 2025, and $1.8 million during Q1 2025.